Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
Jason Seewoodhary1, Leanne Griffin1, Stephen C Bain11Department of Diabetes and Endocrinology, Swansea School of Medicine, University of Wales, Swansea SA2 8PP, UKAbstract: Exenatide (also known as exendin-4) is a glucagon-like peptide-1 mimetic, which is indicated for the treatment of type 2 diabet...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2010-05-01
|
| Series: | Diabetes, Metabolic Syndrome and Obesity |
| Subjects: | |
| Online Access: | https://www.dovepress.com/critical-appraisal-of-once-weekly-formulation-of-exenatide-in-the-cont-peer-reviewed-article-DMSO |
| _version_ | 1797935273065054208 |
|---|---|
| author | Seewoodhary J Griffin Bain S |
| author_facet | Seewoodhary J Griffin Bain S |
| author_sort | Seewoodhary J |
| collection | DOAJ |
| description | Jason Seewoodhary1, Leanne Griffin1, Stephen C Bain11Department of Diabetes and Endocrinology, Swansea School of Medicine, University of Wales, Swansea SA2 8PP, UKAbstract: Exenatide (also known as exendin-4) is a glucagon-like peptide-1 mimetic, which is indicated for the treatment of type 2 diabetes mellitus. The currently available formulation of this drug is a twice-daily exenatide (exenatide BID) injection that should be administered within 60 minutes of food. Once-weekly exenatide (exenatide QW) formulation is now being assessed in a clinical trial program. Exenatide QW has been shown to be the only noninsulin monotherapy to achieve glycosylated hemoglobin levels of <7% in >75% of treated patients. It has also demonstrated potential cardiovascular benefits by lowering total and low-density lipoprotein cholesterol concentrations, triglyceride levels, and both systolic and diastolic blood pressure. In addition, patients treated with exenatide QW achieved significant weight loss, which may also lead to significant cardiovascular risk reduction. Exenatide QW is associated with a lower incidence of gastrointestinal adverse effects compared with exenatide BID, and no patients treated with exenatide QW monotherapy experienced a confirmed hypoglycemic event. Exenatide QW results in 24-hour coverage with exenatide concentrations that are known to improve glycemic control and remain well tolerated in patients with type 2 diabetes mellitus. This review defines the state of play with exenatide QW by critically appraising its role in clinical practice.Keywords: GLP-1 mimetic, HbA1c, weight loss |
| first_indexed | 2024-04-10T18:11:50Z |
| format | Article |
| id | doaj.art-bad96351b7d74267b44ac891c70c9d99 |
| institution | Directory Open Access Journal |
| issn | 1178-7007 |
| language | English |
| last_indexed | 2024-04-10T18:11:50Z |
| publishDate | 2010-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Diabetes, Metabolic Syndrome and Obesity |
| spelling | doaj.art-bad96351b7d74267b44ac891c70c9d992023-02-02T10:44:56ZengDove Medical PressDiabetes, Metabolic Syndrome and Obesity1178-70072010-05-01Volume 31651724451Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitusSeewoodhary JGriffinBain SJason Seewoodhary1, Leanne Griffin1, Stephen C Bain11Department of Diabetes and Endocrinology, Swansea School of Medicine, University of Wales, Swansea SA2 8PP, UKAbstract: Exenatide (also known as exendin-4) is a glucagon-like peptide-1 mimetic, which is indicated for the treatment of type 2 diabetes mellitus. The currently available formulation of this drug is a twice-daily exenatide (exenatide BID) injection that should be administered within 60 minutes of food. Once-weekly exenatide (exenatide QW) formulation is now being assessed in a clinical trial program. Exenatide QW has been shown to be the only noninsulin monotherapy to achieve glycosylated hemoglobin levels of <7% in >75% of treated patients. It has also demonstrated potential cardiovascular benefits by lowering total and low-density lipoprotein cholesterol concentrations, triglyceride levels, and both systolic and diastolic blood pressure. In addition, patients treated with exenatide QW achieved significant weight loss, which may also lead to significant cardiovascular risk reduction. Exenatide QW is associated with a lower incidence of gastrointestinal adverse effects compared with exenatide BID, and no patients treated with exenatide QW monotherapy experienced a confirmed hypoglycemic event. Exenatide QW results in 24-hour coverage with exenatide concentrations that are known to improve glycemic control and remain well tolerated in patients with type 2 diabetes mellitus. This review defines the state of play with exenatide QW by critically appraising its role in clinical practice.Keywords: GLP-1 mimetic, HbA1c, weight losshttps://www.dovepress.com/critical-appraisal-of-once-weekly-formulation-of-exenatide-in-the-cont-peer-reviewed-article-DMSOType 2 DiabetesExenatide QWGLP-1 mimeticHbA1CWeight loss |
| spellingShingle | Seewoodhary J Griffin Bain S Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus Diabetes, Metabolic Syndrome and Obesity Type 2 Diabetes Exenatide QW GLP-1 mimetic HbA1C Weight loss |
| title | Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus |
| title_full | Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus |
| title_fullStr | Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus |
| title_full_unstemmed | Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus |
| title_short | Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus |
| title_sort | critical appraisal of once weekly formulation of exenatide in the control of type 2 diabetes mellitus |
| topic | Type 2 Diabetes Exenatide QW GLP-1 mimetic HbA1C Weight loss |
| url | https://www.dovepress.com/critical-appraisal-of-once-weekly-formulation-of-exenatide-in-the-cont-peer-reviewed-article-DMSO |
| work_keys_str_mv | AT seewoodharyj criticalappraisalofonceweeklyformulationofexenatideinthecontroloftype2diabetesmellitus AT griffin criticalappraisalofonceweeklyformulationofexenatideinthecontroloftype2diabetesmellitus AT bains criticalappraisalofonceweeklyformulationofexenatideinthecontroloftype2diabetesmellitus |